Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aslan Pharmaceuticals Ltd ADR
(NQ:
ASLN
)
1.110
-0.270 (-19.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aslan Pharmaceuticals Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
July 06, 2023
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer.
Via
Benzinga
Dow Tumbles Over 300 Points; US Jobless Claims Increase More Than Projected
July 06, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday. Following the market opening Thursday, the Dow traded down 0.96% to 33,958.13 while the NASDAQ fell 1.06%...
Via
Benzinga
What's Going On With ASLAN Pharmaceuticals Stock Today?
July 06, 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) released topline data from its TREK-AD Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe
Via
Benzinga
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
July 06, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
4 Analysts Have This to Say About ASLAN Pharma
June 26, 2023
Via
Benzinga
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
July 05, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
June 23, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Inks Licensing Deal With Zenyaku Kogyo To Commercialize Eblasakimab In Japan
June 22, 2023
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) inked a strategic licensing deal with Zenyaku Kogyo to develop and
Via
Benzinga
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
June 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
May 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
May 15, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting
April 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
March 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
10 Short Squeeze Candidates: PaxMedica, Blue Apron, MicroStrategy And More
March 20, 2023
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits...
Via
Benzinga
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
March 14, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
March 10, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
March 08, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
February 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
February 24, 2023
Via
Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 24, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
February 24, 2023
It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!
Via
InvestorPlace
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
February 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
February 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.